Clinical Trial Update: Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating a carbonic anhydrase antagonist for subarachnoid hemorrhage was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Vasospasm
• Subarachnoid Hemorrhage

Snippet

Sponsor: University of Florida | Conditions: Acute Cerebrovascular Accident, Vasospasm | Phase 2 | Status: WITHDRAWN